# Genovis > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/genovis). ## Overview Genovis is a Swedish life science tools company that develops and markets enzyme-based products and related technologies for biopharmaceutical research, diagnostics, and drug development. Its portfolio includes SmartEnzymes, antibody labeling and glycan-remodeling technologies, and genomics reagents, with operations centered in Sweden and a U.S. subsidiary supporting North American sales. ## Products & services • SmartEnzymes enzyme products and formats • Antibody labeling and glycan remodeling tools • GlyCLICK technology for ADC workflows • Genomics reagents and RNase inhibitor solutions • Custom products and technical application support - **SmartEnzymes and biochemical analysis** (45%) — Enzyme-based tools used for biochemical and biophysical analysis workflows. - **Antibody conjugation** (30%) — Technologies and reagents for antibody labeling, remodeling, and ADC workflows. - **Genomics** (15%) — Reagents and tools for genomics research, including RNA-related applications. - **Services and custom solutions** (10%) — Application support, customized products, and customer-specific development work. - SmartEnzymes enzyme products and formats - Antibody labeling and glycan remodeling tools - GlyCLICK technology for ADC workflows - Genomics reagents and RNase inhibitor solutions - Custom products and technical application support ## Customers Genovis sells to biopharmaceutical companies, biotech firms, and research organizations that need specialized tools for discovery, preclinical work, clinical development, and manufacturing. Customers use its products to simplify workflows, improve data quality, and support development of biologics, ADCs, gene therapy, and genomics applications. - **Biopharmaceutical developers** (primary) — Buy enzyme tools and conjugation technologies for discovery, preclinical, and clinical development. - **Biotech and advanced therapy companies** (primary) — Use ADC, gene therapy, and targeted delivery tools to build and test therapeutic candidates. - **Research institutions and academia** (secondary) — Purchase reagents and workflow tools for biochemical analysis and genomics research. - **Manufacturing and quality control teams** (secondary) — Use products to verify consistency and support production-stage analytical workflows. - Biopharma companies developing biologic drug candidates - Biotech firms working on ADC, gene therapy, and LNP workflows - Academic and research labs needing specialized enzyme tools - Manufacturing and quality-control teams verifying product consistency - Genomics users seeking reagents for sequencing and RNA workflows ## Geography Genovis is headquartered in Kävlinge, Sweden, where it develops and produces enzyme products and houses central support functions. The company sells across Europe and North America through its Swedish parent and U.S. subsidiary, with local commercial representation in several key markets and a business development presence in Shanghai. - **Europe** (50%) — Swedish parent responsible for European sales and global marketing - **North America** (45%) — Genovis Inc. responsible for North American sales and logistics - **Asia** (5%) — Business development presence in Shanghai supports market access - Headquarters and production are in Kävlinge, Sweden - European sales and global marketing are run from Sweden - North American sales are handled through Genovis Inc. in the U.S. - San Diego serves as a warehouse and logistics center - Local representation supports sales in several key markets ## Strategy Genovis focuses on customer-driven innovation, new product launches, and deeper integration of its tools into customer workflows from discovery through manufacturing. It also uses licensing, intellectual property, and acquisitions to broaden its technology base and expand into adjacent applications such as genomics and ADC development. - **Customer-driven product innovation** (short-term) — Close collaboration with users helps Genovis build tools that fit real workflows and improve adoption. - **Broaden the portfolio through licensing and acquisitions** (medium-term) — Access to proprietary technology expands the addressable market and supports differentiated offerings. - **Embed products across the development chain** (medium-term) — Serving discovery, clinical, and manufacturing stages increases customer lifetime value and product relevance. - Develop customer-driven innovation around workflow pain points - Expand product use across the drug-development value chain - Use licensing and M&A to add proprietary technologies - Launch new products regularly to broaden the portfolio - Strengthen commercial reach in key life science markets ## Risks Genovis faces technology, patent, and launch-execution risk because its business depends on specialized products that must remain differentiated and work reliably in customer workflows. It also has exposure to currency movements, customer investment cycles in life science, and dependence on external production capacity for some products. - **Patent and intellectual property risk** [high] — The company relies on proprietary enzyme and workflow technologies that must be protected from imitation or infringement claims. - **Technology and product launch risk** [high] — New tools must work as expected and gain adoption in scientific workflows, or expected revenue may not materialize. - **Foreign exchange risk** [medium] — Expenses are mainly in SEK while revenue is largely in USD and EUR, creating translation and transaction exposure. - **Customer demand cyclicality** [medium] — Life science customers may delay purchases when research or development budgets tighten. - **Production dependency risk** [medium] — Reliance on external manufacturing capacity for some products can delay launches and constrain supply. - Patent protection may be challenged or bypassed by new technologies - Product launches can fail or be misdirected in a fast-moving market - Some products depend on external production capacity - Customer spending can slow when life science investment weakens - Currency risk is material because costs are mainly SEK and revenue is foreign ## Accounting Genovis reports under IFRS and Swedish rules, with judgment concentrated in acquisition accounting, intangible assets, and foreign currency translation. Investors should watch how acquired technology and customer relationships are valued and amortized, how goodwill is tested for impairment, and how exchange-rate movements affect reported results because revenue and costs are denominated in different currencies. - **Business combinations and intangible assets** — SEQURNA acquisition and any future M&A - **Goodwill impairment** — Reported equity and operating results - **Foreign currency translation** — Operating profit and equity - **Revenue recognition for product and custom orders** — Quarterly comparability - Acquisition accounting for SEQURNA and other deals - Goodwill and intangible asset impairment testing - Amortization of acquired customer relationships and technologies - Foreign currency translation between SEK, USD, and EUR - Revenue timing for product sales and custom solutions --- *Last updated: 2026-08-11T04:04:52.895816+00:00*